探析PARP抑制剂的国内专利技术研究动态  

Development dynamics of patented technology of PARP inhibitors in China

作　　者：李伟[1] 严华[1] LI Wei;YAN Hua(Patent Examination Cooperation ( Beijing) Center of the Patent Office,CNIPA,Beijing 100160,China)

机构地区：[1]国家知识产权局专利局专利审查协作北京中心

出　　处：《中国新药杂志》2019年第16期2009-2014,共6页Chinese Journal of New Drugs

摘　　要：目前,聚腺苷二磷酸核糖聚合酶[poly (ADP-ribose) polymerase,PARP]是癌症治疗的一个新靶点,相关抑制剂的研究已逐渐成为企业和科研人员重点关注的方向。目前全球已上市的PARP抑制剂有奥拉帕利、芦卡帕利和尼拉帕利等,同时还有多种药物正处于临床试验阶段。本文拟对PARP抑制剂的国内申请进行了分析,从国内申请趋势、区域分布、专利技术等多角度出发,分析了国内PARP抑制剂的创新状况,有助于国内制药企业对于该类药物的发展动态进一步认识,并积极开展专利布局。PARP represents an important novel target in cancer therapy,while the research of poly ( ADPribose) polymerase ( PARP) inhibitors is a highly concerned direction for relevant companies and researchers. Olaparib,rucaparib and niraparib are drugs that have been come into the world market so far,and there are also many drugs undergoing clinical trials. This paper analyzed the domestic patent application of PARP inhibitors. From the aspects of patent application trends,distribution region,patented technologies and the domestic applications, aiming to discover the present situation of innovation of PARP inhibitors in China,which would be beneficial to guide the domestic pharmaceutical enterprises to understand the development dynamics of PARP inhibitors and carry out patent layout actively.

关 键 词：PARP抑制剂 申请人 技术领域 专利技术 卵巢癌 

分 类 号：R95[医药卫生—药学]